Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease
NCT ID: NCT06300788
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2024-05-27
2026-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia
NCT00374712
The Impact of Phosphate Metabolism on Healthy Aging
NCT03771105
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
NCT04239391
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06794996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKD group
Patient with chronic kidney disease
PPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
Dialysis group
Dialysis patients (hemodialysis or peritoneal dialysis)
PPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
kidney transplant group
Kidney transplant patients
PPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
Control group
Control group of patients with normal renal function
PPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minor patients (\<18 years)
* Patients of both sexes
* Informed patients and parents who have signed the informed consent form
* Patients affiliated to social security
Control group :
\- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up
CKD groups :
* Patients on dialysis for more than 3 months, regardless of technique
* Kidney transplant patients
* Patients with CKD, whatever the cause
Exclusion Criteria
* Treatments that may modify PPi concentration (e.g. bisphosphonates)
0 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Nice - Hôpital de l'Archet 2
Nice, Alpes-Maritimes, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-AOI-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.